Therapeutic potential of cannabinoids in neurodegenerative disorders: A selective review

Current Pharmaceutical Design

Volumn 20, Issue 13, 2014, Pages 2218-2230

  Velayudhan, Latha ^a   van Diepen, Erik ^b   Marudkar, Mangesh ^b   Hands, Oliver ^b   Suribhatla, Srinivas ^b   Prettyman, Richard ^b   Murray, Jonathan ^a   Baillon, Sarah ^a   Bhattacharyya, Sagnik ^c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b LEICESTERSHIRE PARTNERSHIP NHS TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Brain ischemia; Cannabinoid; Huntington's disease; Multiple sclerosis; Parkinson's disease; Tourette's syndrome

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID RECEPTOR; CANNABIS; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; HU 201; LEVONANTRADOL; PLACEBO; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN ISCHEMIA; DEGENERATIVE DISEASE; DRUG TARGETING; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUNTINGTON CHOREA; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; ANIMAL; HUNTINGTON DISEASE; NEURODEGENERATIVE DISEASES; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BRAIN ISCHEMIA; CANNABINOIDS; ENDOCANNABINOIDS; HUMANS; HUNTINGTON DISEASE; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 84903702089     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990434     Document Type: Review

References (229)

1. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification Cannabinoid Receptors Pharmacological Rev 2002; 54(2): 161-202.
2. Devane W, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 1992; 258(5090): 1946-9.
3. Bisogno T, Di Marzo V. The role of the endocannabinoid system in Alzheimer's disease: Facts and hypotheses. Current pharmaceutical design 2008; 14(23): 2299-305.
4. Jackson SJ, Diemel LT, Pryce G, Baker D. Cannabinoids and neuroprotection in CNS inflammatory disease. J Neurol Sci 2005; 233(1-2): 21-5.
5. Cabral GA, Griffin-Thomas L. Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocr Metab Immune Disord Drug Targets 2008; 8(3): 159-72. Epub 2008/09/11.
6. Orgado JM, Fernandez-Ruiz J, Romero J. The endocannabinoid system in neuropathological states. Int Rev Psychiatry 2009; 21(2): 172-80.
7. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366(9503): 2112-7.
8. Walsh DM, Selkoe DJ. A beta oligomers -a decade of discovery. J Neurochem 2007; 101(5): 1172-84.
9. Mi K, Johnson GV. The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2006; 3(5): 449-63.
10. Jellinger KA. Alzheimer 100--highlights in the history of Alzheimer research. J Neural Transm 2006; 113(11): 1603-23.
11. Piazzi L, Rampa A, Bisi A, et al. 3-(4-[[Benzyl(methyl) amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J Med Chem 2003; 46(12): 2279-82.
12. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007; 184(1-2): 69-91.
13. Rampa A, Bisi A, Belluti F, et al. Acetylcholinesterase inhibitors for potential use in Alzheimer's disease: molecular modeling, synthesis and kinetic evaluation of 11H-indeno-[1,2-b]-quinolin-10-ylamine derivatives. Bioorganic Med Chem 2000; 8(3): 497-506.
14. Mancuso C, Siciliano R, Barone E, Butterfield DA, Preziosi P. Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before. Exp Opinion Investigational Drugs 2011; 20(9): 1243-61.
15. Schaeffer EL, Gattaz WF. Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology 2008; 198(1): 1-27.
16. Heneka MT, Kummer MP, Weggen S, et al. Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease. Curr Alzheimer Res 2011; 8(2): 115-31.
17. Arbel M, Solomon B. Immunotherapy for Alzheimer's disease: attacking amyloid-beta from the inside. Trends Immunol 2007; 28(12): 511-3.
18. Boothby LA, Doering PL. Vitamin C and vitamin E for Alzheimer's disease. Annals Pharmacotherap 2005; 39(12): 2073-80.
19. Jiang Q, Heneka M, Landreth GE. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 2008; 22(1): 1-14.
20. Karl T, Cheng D, Garner B, Arnold JC. The therapeutic potential of the endocannabinoid system for Alzheimer's disease. Exp opinion Therapeut Targets 2012; 16(4): 407-20.
21. Riedel G, Davies SN. Cannabinoid function in learning, memory and plasticity. Handbook Exp Pharmacol 2005(168): 445-77.
22. Benito C, Tolon RM, Pazos MR, Nunez E, Castillo AI, Romero J. Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol 2008; 153(2): 277-85.
23. Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neuroscience: the official J Soc Neurosci 2005; 25(8): 1904-13.
24. Eubanks LM, Rogers CJ, Beuscher AEt, et al. A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm 2006; 3(6): 773-7.
25. Esposito G, De Filippis D, Steardo L, et al. CB1 receptor selective activation inhibits beta-amyloid-induced iNOS protein expression in C6 cells and subsequently blunts tau protein hyperphosphorylation in co-cultured neurons. Neurosci Lett 2006; 404(3): 342-6.
26. Mazzola C, Micale V, Drago F. Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur J Pharmacol 2003; 477(3): 219-25.
27. Martin-Moreno AM, Reigada D, Ramirez BG, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol 2011; 79(6): 964-73.
28. Esposito G, Scuderi C, Valenza M, et al. Cannabidiol reduces Abeta-induced neuroinflammation and promotes hippocampal neurogenesis through PPARgamma involvement. PLoS One 2011; 6(12): e28668.
29. Benito C, Nunez E, Tolon RM, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 2003; 23(35): 11136-41.
30. Nunez E, Benito C, Tolon RM, Hillard CJ, Griffin WS, Romero J. Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience 2008; 151(1): 104-10.
31. Fadda P, Robinson L, Fratta W, Pertwee R, Riedel G. Differential effects of THC-or CBD-rich cannabid extracts on working memory in rats. Neuropharmacology 2004; 47(8): 1170-9.
32. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. Modulation of mediotemporal and ventrostriatial function in humans by delta-9-tetrahydrocannabinol: a neural basis for the effects of cannabis sativa on learning and psychosis. Archiv General Psychiatry 2009; 66(4): 442-51.
33. Englund A, Morrison P, Nottage J, et al. Cannabidiol inhibits THCelicited paranoid symptoms and hippocampal-dependent memory impairment. Psychopharmacology (Berl) 2013; 27(1): 19-27.
34. Morgan CJA, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected].[Erratum appears in Br J Psychiatry 2010 Nov; 197: 416]. Br J Psychiatry 2010; 197(4): 285-90.
35. Bhattacharyya S, Morrison P, Fusar-Poli P, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function. Neuropsychopharmacology 2010; 35(3): 764-74.
36. Bhattacharyya S, Crippa JAS, Allen P, et al. Induction of psychosis by delta-9-tetrahydrocannabinol reflects modulation of prefrontal and striatial function during attentional salience processing. Archiv General Psychiatry 2012; 69(1): 27-36.
37. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12(9): 913-9.
38. Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) 2006; 185(4): 524-8.
39. Passmore MJ. The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation. Int J Geriatric Psychiatry 2008; 23(1): 116-7.
40. Martin-Sandos R, Crippa JAS, Batalla A, et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des 2012; 18(32): 4966-79.
41. Crippa JAS, Zuardi AW, Martin-Sandos R, et al. Cannabis and anxiety: a critical review of the evidence. Human Psychopharmacol 2009; 24(7): 515-23.
42. Schoeler T, Bhattacharyya S. The effects of canabis use on memory function: an update. Substance Abuse Rehabilitation 2013; 2013: 4: 11-27.
43. Bhattacharyya S, Sendt KV. Neuroimaging evidence for cannabinoid modulation of cognition and affect in man. Frontiers Behavioral Neurosci 2012; 6.
44. Bhattacharyya S, Crippa JAS, Martin-Sandos R, Winton-Brown T, Fusar-Poli P. Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. Curr Pharm Des 2009; 15(22): 2603-14.
45. Bhattacharyya S, Atakan Z, Martin-Sandos R, Crippa JAS, McGuire P. Neural mechanisms for the cannabinoid modulation of cognition and affect in man: a critical review of neuroimaging studies. Curr Pharm Des 2012; 18(32): 5045-54.
46. Bhattacharyya S, Atakan Z, Martin-Sandos R, et al. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: A preliminary report of the modulation of the effects of delta-9-THC on midbrain and striatial function by AKT1 and DAT1 genotypes. Mol Psychiatry 2012; Jan 31.
47. Morrison P, Nottage J, Stone J, et al. Disruption of frontal coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology 2011; 36(4): 827-36.
48. Stone J, Morrison P, Brugger S, et al. Communication breakdown: delta-9 tetrahydrocannabinol effects on pre-speech neural coherence. Mol Psychiatry 2012; 17(6): 568-9.
49. Hallak JE, Dursun SM, Bosi DC, et al. The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(1): 198-202.
50. Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 2011; 6(4): 237-49.
51. Rampa A, Bartolini M, Bisi A, et al. The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease? Acs Med Chem Lett 2012; 3(3): 182-6.
52. Parkinson's Disease Society. Parkinson's and you. An introduction to Parkinson's disease 2005; Available from: http: //www.parkinsons.org.uk/advice/publications/booklets/living-withparkinsons. aspx.
53. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington -clinical, morphological and neurochemical correlations. J Neurological Sci 1973; 20: 415-25.
54. Fernandez-Ruiz J, Moreno-Martet M, Rodriguez-Cueto C, et al. Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 2011; 163(7): 1365-78.
55. Pisani V, Madeo G, Tassone A, et al. Homeostatic changes of the endocannabinoid system in Parkinson's disease. Mov Disord 2011; 26(2): 216-22.
56. El Khoury MA GV, Moutsimilli L, Giros B, Tzavara ET. Interactions between the cannabinoid and dopaminergic systems: Evidence from animal studies. Progress in Neuropsychopharmacology and Biological Psychiatry 2012.
57. Garcia-Arencibia M, Garcia C, Fernandez-Ruiz J. Cannabinoids and Parkinson's disease. CNS Neurol Disord Drug Targets 2009; 8(6): 432-9.
58. Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004; 63(7): 1245-50.
59. Morgese MG, Cassano T, Cuomo V, Giuffrida A. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp Neurol 2007; 208(1): 110-9.
60. Meschler JP, Howlett AC, Madras BK. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated nonhuman primates. Psychopharmacology (Berl) 2001; 156(1): 79-85.
61. Sanudo-Pena MC, Patrick SL, Khen S, Patrick RL, Tsou K, Walker JM. Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease. Neurosci Lett 1998; 248(3): 171-4.
62. Kelsey JE, Harris O, Cassin J. The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. Behav Brain Res 2009; 203(2): 304-7.
63. Gonzalez S, Scorticati C, Garcia-Arencibia M, de Miguel R, Ramos JA, Fernandez-Ruiz J. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res 2006; 1073-1074: 209-19.
64. van der Stelt M, Fox SH, Hill M, et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. Faseb J 2005; 19(9): 1140-2.
65. Fernandez-Espejo E, Caraballo I, de Fonseca FR, et al. Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis 2005; 18(3): 591-601.
66. Cao X, Liang L, Hadcock JR, et al. Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J Pharmacol Exp Ther 2007; 323(1): 318-26.
67. Morgese MG, Cassano T, Gaetani S, et al. Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochem Int 2009; 54(1): 56-64.
68. Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2002; 17(6): 1180-7.
69. Garcia-Arencibia M, Gonzalez S, de Lago E, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 2007; 1134(1): 162-70.
70. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 2005; 19(1-2): 96-107.
71. Price DA, Martinez AA, Seillier A, et al. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci 2009; 29(11): 2177-86.
72. Garcia C, Palomo-Garo C, Garcia-Arencibia M, Ramos J, Pertwee R, Fernandez-Ruiz J. Symptom-relieving and neuroprotective effects of the phytocannabinoid [Greek capital Delta]9-THCV in animal models of Parkinson's disease. Br J Pharmacol 2011; 163(7): 1495-506.
73. Jimenez-Del-Rio M, Daza-Restrepo A, Velez-Pardo C. The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson's disease. Neurosci Res 2008; 61(4): 404-11.
74. Tadaiesky M, Dombrowski P, Da Cunha C, Takahashi R. Effects of SR141716A on Cognitive and Depression-Related Behavior in an Animal Model of Premotor Parkinson's Disease. Parkinsons Disease 2010; 2010: 238491.
75. Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986; 30(4): 277-82.
76. Frankel JP, Hughes A, Less AJ, Stern GM. Marijuana for parkinsonian tremor. J Neurol Neurosurg Psychiatry 1990; 53(5): 436.
77. Mesnage V, Houeto JL, Bonnet AM, et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin Neuropharmacol 2004; 27(3): 108-10.
78. Venderova K, Ruzicka E, Vorisek V, Visnovsky P. Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms. Mov Disord 2004; 19(9): 1102-6.
79. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001; 57(11): 2108-11.
80. Zuardi AW, Crippa JAS, Hallak JEC, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol 2009; 23(8): 979-83.
81. Little JP, Villanueva EB, Klegeris A. Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease. Mini Rev Med Chem 2011; 11(7): 582-90.
82. Carroll C, Zeissler M, Hanemann C, Zajicek J. Δ(9) -THC exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. Neuropathol Applied Neurobiol 2012.
83. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 2005; 6(12): 919-30.
84. Kumar P, Kalonia H, Kumar A. Huntington's disease: pathogenesis to animal models. Pharmacol Rep 2010; 62(1): 1-14.
85. Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011; 50(2): 193-211.
86. Begg M, Pacher P, Batkai S, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106(2): 133-45.
87. Chiodi V, Uchigashima M, Beggiato S, et al. Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington's disease. Neurobiol Dis 2012; 45(3): 983-91.
88. Casteels C, Vandeputte C, Rangarajan JR, et al. Metabolic and type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease. Exp Neurol 2011; 229(2): 440-9.
89. Mievis S, Blum D, Ledent C. Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol Dis 2011; 42(3): 524-9.
90. Casteels C, Martinez E, Bormans G, et al. Type 1 cannabinoid receptor mapping with [18F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism. Eur J Nucl Med Mol Imaging 2010; 37(12): 2354-63.
91. Lastres-Becker I, Berrendero F, Lucas JJ, et al. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease. Brain Res 2002; 929(2): 236-42.
92. Wolfgang WJ, Miller TW, Webster JM, et al. Suppression of Huntington's disease pathology in Drosophila by human singlechain Fv antibodies Proc Natil Acad Sci 2005; 102(32): 11563-8.
93. Scotter E, Goodfellow C, Graham E, Dragunow M, Glass M. Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. Br J Pharmacol 2010; 160(3): 747-61.
94. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 1990; 346(6284): 561-4.
95. Gerard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991; 279(Pt 1): 129-34.
96. Van Laere K, Casteels C, Dhollander I, et al. Widespread Decrease of Type 1 Cannabinoid Receptor Availability in Huntington Disease In vivo J Nuclear Med 2010; 51(9): 1413-7.
97. Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000; 97(3): 505-19.
98. Palazuelos J, Aguado T, Pazos MR, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009; 132(Pt 11): 3152-64.
99. Runne H, Régulier E, Kuhn A, et al. Dysregulation of Gene Expression in Primary Neuron Models of Huntington's Disease Shows That Polyglutamine-Related Effects on the Striatal Transcriptome May Not Be Dependent on Brain Circuitry J Neurosci 2008; 28(39): 9723-31.
100. Dowie MJ, Bradshaw HB, Howard ML, et al. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience 2009; 163(1): 456-65.
101. Allen KL, Waldvogel HJ, Glass M, Faull RLM. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease. J Chem Neuroanat 2009; 37(4): 266-81.
102. Sagredo O, Gonzalez S, Aroyo I, et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 2009; 57(11): 1154-67.
103. Pazos MR, Sagredo O, Fernandez-Ruiz J. The endocannabinoid system in Huntington's disease. Curr Pharm Des 2008; 14(23): 2317-25.
104. de Lago E, Fernandez-Ruiz J. Cannabinoids and neuroprotection in motor related disorders. CNS and Neurological Disorders -Drug Target 2007; 6(6): 377-87.
105. Fernandez-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 2009; 156(7): 1029-40.
106. Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis 1998; 5(6 Pt B): 534-51.
107. Muller-Vahl K, Schneider U, Emrich I. Nabilone increases choreatic movements in Huntington's disease. Mov Disord 1999; 14: 1038-40.
108. Curtis A, Mitchell I, Patel S, Ives N, Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord 2009; 24(15): 2254-9.
109. Curtis A, Rickards H. Nabilone could treat chorea and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci 2006; 18(4): 553-4.
110. Sagredo O, Pazos M, Valdeolivas S, Fernandez-Ruiz J. Cannabinoids: novel medicines for the treatment of Huntington's disease. Recent Patents CNS Drug Discov 2012; 7(1): 41-8.
111. Calabrese P. Neuropsychology of multiple sclerosis--an overview. J Neurol 2006; 253 Suppl 1: I10-5.
112. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372(9648): 1502-17.
113. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997; 38(1): 44-8.
114. Somerset M, Campbell R, Sharp DJ, Peters TJ. What do people with MS want and expect from health-care services? Health Expect 2001; 4(1): 29-37.
115. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004; 62(11): 2098-100.
116. Bahr B, Karanian D, Makanji S, Makriyannis A. Targeting the endocannabinoid system in treating brain disorders. Exp Opinion Investigational Drugs 2006; 15(4): 351-65.
117. Centonze D, Bari M, Rossi S, et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain 2007; 130(Pt 10): 2543-53.
118. Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003; 302(5642): 84-8.
119. Shen M, Piser TM, Seybold VS, Thayer SA. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 1996; 16(14): 4322-34.
120. Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N-and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 1997; 78(1): 43-50.
121. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998; 95(14): 8268-73.
122. Docagne F, Muneton V, Clemente D, et al. Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Mol Cell Neurosci 2007; 34(4): 551-61.
123. Loría F, Petrosino S, Hernangómez M, et al. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol Dis 2010; 37(1): 166-76.
124. Yiangou Y, Facer P, Durrenberger P, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 2006; 6: 12.
125. Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152(7): 1092-101.
126. Molina-Holgado E, Vela JM, Arevalo-Martin A, et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 2002; 22(22): 9742-53.
127. Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003; 23(7): 2511-6.
128. Arevalo-Martin A, Garcia-Ovejero D, Gomez O, et al. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. Br J Pharmacol 2008; 153(2): 216-25.
129. Bisogno T, Di Marzo V. Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets 2010; 9(5): 564-73.
130. Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. Faseb J 2001; 15(2): 300-2.
131. Cabranes A, Venderova K, de Lago E, et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis 2005; 20(2): 207-17.
132. Cabranes A, Pryce G, Baker D, Fernandez-Ruiz J. Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Brain Res 2006; 1107(1): 199-205.
133. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 2005; 95(2): 437-45.
134. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000; 404(6773): 84-7.
135. Buccellato E, Carretta D, Utan A, et al. Acute and chronic cannabinoid extracts administration affects motor function in a CREAE model of multiple sclerosis. J Ethnopharmacol 2011; 133(3): 1033-8.
136. Mestre L, Correa F, Arevalo-Martin A, et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem 2005; 92(6): 1327-39.
137. Pryce G, Ahmed Z, Hankey DJR, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003; 126(Pt 10): 2191-202.
138. Pryce G, Baker D. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 2007; 150(4): 519-25.
139. Maresz K, Pryce G, Ponomarev ED, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 2007; 13(4): 492-7.
140. La Rana G, Russo R, Campolongo P, et al. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J Pharmacol Exp Ther 2006; 317(3): 1365-71.
141. Robles EMS, Arias AB, Fontelles MIM. Cannabinoids and muscular pain. Effectiveness of the local administration in rat. Eur J Pain 2012.
142. Correa F, Docagne F, Mestre L, et al. Cannabinoid system and neuroinflammation: implications for multiple sclerosis. Neuroimmunomodulation 2007; 14(3-4): 182-7.
143. Xu H, Cheng CL, Chen M, et al. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol 2007; 82(3): 532-41.
144. de Lago E, Moreno-Martet M, Cabranes A, Ramos J, Fernández-Ruiz J. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology 2012; 62(7): 2298-307.
145. Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB. Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 1989; 23(1): 73-81.
146. Jean-Gilles L, Feng S, Tench CR, et al. Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 2009; 287(1-2): 212-5.
147. Benito C, Romero JP, Tolon RM, et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 2007; 27(9): 2396-402.
148. Ramil E, Sanchez AJ, Gonzalez-Perez P, et al. The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from Spain. Mult Scler 2010; 16(2): 139-46.
149. Rossi S, Buttari F, Studer V, et al. The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis. Mult Scler 2011; 17(3): 281-8.
150. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362(9395): 1517-26.
151. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76(12): 1664-9.
152. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10(4): 434-41.
153. Zajicek J, Hobart J, Slade A, Barnes D, Mattison PG, Group MR. Mutliple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurgery Psychiatry 2012; 83(11): 1125-32.
154. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebocontrolled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006; 17(6): 636-41.
155. Pertwee RG. Cannabinoids and multiple sclerosis. Mol Neurobiol 2007; 36(1): 45-59.
156. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003; 290(13): 1757-62.
157. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004; 329(7460): 253.
158. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65(6): 812-9.
159. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Metaanalysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007; 23(1): 17-24.
160. Ghaffar O, Feinstein A. Multiple sclerosis and cannabis: a cognitive and psychiatric study. Neurology 2008; 71(3): 164-9.
161. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10(4): 417-24.
162. Aragona M, Onesti E, Tomassini V, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol 2009; 32(1): 41-7.
163. Jackson SJ, Diemel LT, Pryce G, Baker D. Cannabinoids and neuroprotection in CNS inflammatory disease. J Neurol Sci 2005; 233(1-2): 21-5.
164. Clinical Neurology Research Group CUPID -Latest news 2012 [12/12/12]; Available from: http://sites.pcmd.ac.uk/cnrg/files/cupid/CUPID_results_press_release_web.pdf.
165. Wade DT, Makela PM, House H, Bateman C, Robson P. Longterm use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12(5): 639-45.
166. Wang T, Collet J-P, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. Canadian Med Assoc J 2008; 178(13): 1669-78.
167. Romero J, Orgado JM. Cannabinoids and neurodegenerative diseases. CNS Neurol Disord Drug Targets 2009; 8(6): 440-50.
168. Martinez-Orgado J, Fernandez-Lopez D, Lizasoain I, Romero J. The seek of neuroprotection: introducing cannabinoids. Recent Patents CNS Drug Discov 2007; 2(2): 131-9.
169. Hayakawa K, Mishima K, Fujiwara M. Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke. Pharmaceuticals 2010; 3: 2197-212.
170. Hillard CJ. Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr Pharm Des 2008; 14(23): 2347-61.
171. Castillo A, Tolon MR, Fernandez-Ruiz J, Romero J, Martinez-Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis 2010; 37(2): 434-40.
172. Nagayama T, Sinor AD, Simon RP, et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neuroscience 1999; 19(8): 2987-95.
173. Sinor AD, Irvin SM, Greenberg DA. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett 2000; 278(3): 157-60.
174. Fernandez-Lopez D, Martinez-Orgado J, Nunez E, et al. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatr Res 2006; 60(2): 169-73.
175. Fernández-López D, Faustino J, Derugin N, et al. Reduced infarct size and accumulation of microglia in rats treated with WIN 55,212-2 after neonatal stroke. Neuroscience 2012; 207: 307-15.
176. Natarajan V, Reddy PV, Schmid PC, Schmid HH. On the biosynthesis and metabolism of N-acylethanolamine phospholipids in infarcted dog heart. Biochim Biophys Acta 1981; 664(2): 445-8.
177. Schmid PC, Krebsbach RJ, Perry SR, Dettmer TM, Maasson JL, Schmid HH. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett 1995; 375(1-2): 117-20.
178. Felder CC, Nielsen A, Briley EM, et al. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett 1996; 393(2-3): 231-5.
179. Kempe K, Hsu FF, Bohrer A, Turk J. Isotope dilution mass spectrometric measurements indicate that arachidonylethanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or is absent from fresh tissue. J Biol Chem 1996; 271(29): 17287-95.
180. Patel S, Carrier EJ, Ho WSV, et al. The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. J Lipid Res 2005; 46(2): 342-9.
181. Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ. Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 2004; 129(3): 743-50.
182. Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, Schmid HHO. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem 2004; 88(5): 1159-67.
183. Amantea D, Spagnuolo P, Bari M, et al. Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17beta-estradiol. Febs J 2007; 274(17): 4464-775.
184. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 2003; 23(21): 7767-75.
185. Grundy RI, Rabuffetti M, Beltramo M. Cannabinoids and neuroprotection. Mol Neurobiol 2001; 24(1-3): 29-51.
186. Fowler CJ, Tiger G, Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S, Ramos JA. Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin. J Enzyme Inhib Med Chem 2003; 18(3): 225-31.
187. Mechoulam R, Hanus L. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. Chem Phys Lipids 2002; 121(1-2): 35-43.
188. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet neurol 2003; 2(5): 291-8.
189. Hayakawa K, Mishima K, Abe K, et al. Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. Neuroreport 2004; 15(15): 2381-5.
190. Leker RR, Gai N, Mechoulam R, Ovadia H. Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke 2003; 34(8): 2000-6.
191. Louw DF, Yang FW, Sutherland GR. The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res 2000; 857(1-2): 183-7.
192. Mauler F, Hinz V, Augstein KH, Fassbender M, Horvath E. Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Brain Res 2003; 989(1): 99-111.
193. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neuroscience 2002; 22(22): 9771-5.
194. Zani A, Braida D, Capurro V, Sala M. Delta9-tetrahydrocannabinol (THC) and AM 404 protect against cerebral ischaemia in gerbils through a mechanism involving cannabinoid and opioid receptors. Br J Pharmacol 2007; 152(8): 1301-11.
195. Pellegrini-Giampietro DE, Mannaioni G, Bagetta G. Post-ischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death. Febs J 2009; 276(1): 2-12.
196. Suzuki N, Suzuki M, Murakami K, Hamajo K, Tsukamoto T, M S. Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates. Brain Res 2012; 1430: 93-100.
197. Cernak I, Vink R, Natale J, et al. The dark side of endocannabinoids: a neurotoxic role for anandamide. J Cereb Blood Flow Metab 2004; 24(5): 564-78.
198. Walther S, Halpern M. Cannabinoids and Dementia: A Rev Clin Preclinical Data Pharm 2010; 3: 2689-708.
199. Ramirez S, Haskó J, Skuba A, et al. Activation of Cannabinoid Receptor 2 Attenuates Leukocyte-Endothelial Cell Interactions and Blood-Brain Barrier Dysfunction under Inflammatory Conditions. J Neuroscience 2012; 32(12): 4004-16.
200. Schabitz W-R, Giuffrida A, Berger C, et al. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke 2002; 33(8): 2112-4.
201. Panikashvili D, Simeonidou C, Ben-Shabat S, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413(6855): 527-31.
202. Sugiura T, Yoshinaga N, Kondo S, Waku K, Ishima Y. Generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in picrotoxinin-administered rat brain. Biochem Biophys Res Commun 2000; 271(3): 654-8.
203. Ducros A, Boukobza M, Porcher R, Sarov M, Valade D, Bousser MG. The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients. Brain 2007; 130(Pt 12): 3091-101.
204. Geibprasert S, Gallucci M, Krings T. Addictive illegal drugs: structural neuroimaging. AJNR Am J Neuroradiol 2010; 31(5): 803-8.
205. Morgan CJA, Curran HV. Effects of cannabidiol on schizophrenialike symptoms in people who use cannabis. Br J Psychiatry 2008; 192(4): 306-7.
206. Muller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 2003; 28(2): 384-8.
207. Berding G, Muller-Vahl K, Schneider U, et al. [123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. Biol Psychiatry 2004; 55(9): 904-15.
208. Curtis A, Clarke CE, Rickards HE. Cannabinoids for Tourette's Syndrome. Cochrane Database Syst Rev 2009(4): CD006565.
209. Beghi E, Logroscino G, Chio A, et al. The Epidemiology of ALS and the role of population based registries. Biochim Biophys Acta 2006; 1762: 1150-7.
210. Mitchell J, Borasio G. Amyotrophic lateral sclerosis. Lancet 2007; 369: 2031-41.
211. Kew J, Goldstein L, Leigh P. The relationship between cognitive function and cerebral activation in amyotrophic lateral sclerosis -a psychological and positron emission study. Brain 1993; 116: 1399-423
212. Pasinelli P, Brown R. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nature Rev Neuroscience 2006; 7: 710-23.
213. Banack S, Murch S. Multiple neurotoxic items in the Chamarro diet link BMAA with ALS/PDC. Amyotrophic Lateral Sclerosis Frontotemporal Degeneration 2009; 10(2): 34-40.
214. Kamel F, Umbach D, Bedlack R, et al. Pesticide exposure and amyotrophic lateral sclerosis. Neurotoxicology 2012; 33(3): 457-62.
215. Chen H, Richard M, Sandler D, Umbach D, Kamel F. Head injury and amyotrophic lateral sclerosis. Am J Epidemiol 2007; 166(7): 810-6.
216. Chio A, Calvo A, Moglia C, Mazzini L, Mora G. Phenotypic heterogeneity of amyotrophic lateral sclerosis: A population based study. J Neurol Neurosurgery Psychiatry 2011; 82: 740-6.
217. Boillee S, Yamanaka K, Lobsiger C, et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006; 312(5778): 1389-92.
218. Choi D. Excitotoxic cell death. J Neurobiol 1992; 23(9): 1261-76.
219. Rossi S, De Chiara V, Musella A, et al. Abormal sensitivity of cannabinoid CBI receptors in the striatum of mice with experimental ALS. Amyotrophic Lateral Sclerosis Frontotemporal Degeneration 2010; 11: 83-90.
220. Zhao P, Ignacio D, Beattie E, Abood M. Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurones of ALS mice: implications for excitotoxicity. Eur J Neurosci 2008; 27: 572-9.
221. Kim K, Moore D, Makriyannis A, Aboud M. AM 1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol 2006; 542: 100-5.
222. Shoemaker J, Seely K, Reed R, Crow J, Prather P. The CB2 cannabinoid agonist AM 1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J Neurochem 2007; 101: 87-98.
223. Raman C, McAllister S, Rizvi G, Patel S, Moore D, Abood M. Amyotrophic Lateral Sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotrophic Lateral Sclerosis other Motor Neuron Disorders 2004; 5: 33-9.
224. Weydt P, Hong S, Witting A, Moller T, Stella N, Kilot M. Cannabinoid delays symptom onset in S0D1 (G93A) transgenic mice without affecting survival. Amyotrophic Lateral Sclerosis Other Motor Neuron Disorders 2005; 6: 182-4.
225. Bilsland L, Dick J, Pryce G, et al. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in S0D1 mice. The FASEB Journal 2006; 20: 1003-5.
226. Carter G, Rosen B. Marijuana in the management of amyotrophic lateral sclerosis. Am J Hospice Palliative Care 2001; 18(4): 264-70.
227. Amtmann D, Weydt P, Johnson K, Jensen M, Carter G. Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hospice Palliative Care 2004; 21: 95-104.
228. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. New Eng J Med 1994; 330(9): 585-91.
229. Bensimon G, Doble A. The tolerability of riluzole in the treatment of patients with amyotrophic lateral sclerosis. Exp Opinion Drug Safety 2004; 3: 525-34.